Search results
Moderna’s sales from its only product, the COVID-19 vaccine, fell 91% from last year
Fortune via Yahoo Finance· 2 days agoModerna’s next focus is to continue rolling out mRNA vaccines, which teaches cells how to make the...
Moderna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript
Insider Monkey via Yahoo Finance· 12 hours agoModerna, Inc. (NASDAQ:MRNA) Q1 2024 Earnings Call Transcript May 2, 2024 Moderna, Inc. beats...
Moderna Breaks Out For The First Time In A Year After Covid Shot Wallops Sales Views
Investor's Business Daily· 2 days agoBut that beat projections for a loss of $3.56 per share. Moderna says the European Union is planning...
Moderna plants new solid tumor trials for cancer vaccine, weeds PD-1 work after review
FierceBiotech· 2 days agoMuch of Moderna’s focus is on nabbing FDA approval for a respiratory syncytial virus vaccine, a...
Moderna COVID vaccine sales plummet 91 percent - The Boston Globe
The Boston Globe· 2 days agoSales of Moderna’s COVID-19 vaccine plunged 91 percent from the previous year for the first quarter...
Moderna posts better-than-expected quarterly results as it looks to fall RSV vaccine launch
Market Watch· 3 days agoA Food and Drug Administration decision on approval of Moderna’s RSV vaccine is expected by May 12,...
Moderna (MRNA) Gears Up for Q1 Earnings: Here's What to Expect
Zacks via Yahoo Finance· 5 days agoInvestors' focus will likely be on updates on Moderna's (MRNA) expected RSV vaccine launch and its...
Moderna stock surges 15% after it beat earnings expectations despite plummeting COVID vaccine sales
Quartz· 3 days agoModerna stock soared on Thursday after its first-quarter earnings report sailed past Wall Street’s...
Moderna Stock Takes Minimal Hit After New COVID Vaccine Topped Projected Estimates
Black Enterprise· 2 days agoModerna announced an increase in stock price after their COVID vaccine exceeded sales estimates for...
Moderna Q1 earnings: lower-than-expected loss of $1.18 billion sets tone for vaccine launch | Invezz
Invezz· 3 days agoModerna Inc (NASDAQ: MRNA) reported a narrower-than-expected loss for the first quarter of the year,...